Insider Selling: Janux Therapeutics (NASDAQ:JANX) VP Sells $28,878.46 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) VP Maria Dobek sold 2,038 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $14.17, for a total value of $28,878.46. Following the completion of the sale, the vice president directly owned 32,270 shares of the company’s stock, valued at $457,265.90. The trade was a 5.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Janux Therapeutics Price Performance

Janux Therapeutics stock opened at $13.89 on Friday. The stock has a market capitalization of $847.07 million, a price-to-earnings ratio of -7.55 and a beta of 2.58. Janux Therapeutics, Inc. has a 1-year low of $12.12 and a 1-year high of $35.34. The business has a fifty day moving average price of $14.42 and a 200-day moving average price of $17.02.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.13. The business had revenue of $3.73 million during the quarter, compared to analyst estimates of $4.36 million. On average, equities research analysts anticipate that Janux Therapeutics, Inc. will post -1.71 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on JANX. Weiss Ratings raised Janux Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, April 22nd. JonesTrading lowered their price objective on Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating for the company in a research report on Tuesday, April 28th. Evercore set a $22.00 price objective on Janux Therapeutics in a research report on Monday. Barclays cut Janux Therapeutics from an “overweight” rating to an “underweight” rating and lowered their price objective for the stock from $29.00 to $14.00 in a research report on Monday, April 20th. Finally, UBS Group cut Janux Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $57.00 to $15.00 in a research report on Wednesday, April 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $45.85.

Hedge Funds Weigh In On Janux Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC raised its stake in Janux Therapeutics by 13.8% in the 4th quarter. Janus Henderson Group PLC now owns 5,350,453 shares of the company’s stock worth $73,850,000 after acquiring an additional 649,341 shares during the last quarter. State Street Corp raised its stake in Janux Therapeutics by 103.8% in the 4th quarter. State Street Corp now owns 3,853,951 shares of the company’s stock worth $53,185,000 after acquiring an additional 1,962,486 shares during the last quarter. Vanguard Group Inc. raised its stake in Janux Therapeutics by 10.4% in the 3rd quarter. Vanguard Group Inc. now owns 2,417,104 shares of the company’s stock worth $59,074,000 after acquiring an additional 227,676 shares during the last quarter. Prosight Management LP raised its stake in Janux Therapeutics by 176.5% in the 4th quarter. Prosight Management LP now owns 2,392,523 shares of the company’s stock worth $33,017,000 after acquiring an additional 1,527,173 shares during the last quarter. Finally, Orbimed Advisors LLC raised its stake in Janux Therapeutics by 10.7% in the 4th quarter. Orbimed Advisors LLC now owns 1,954,426 shares of the company’s stock worth $26,971,000 after acquiring an additional 188,326 shares during the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.